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Abstract
Background: Though the management of malignancies has improved vastly in recent years, many treatment
options lack the desired efficacy and fail to adequately augment patient morbidity and mortality. It is increasingly
clear that patient response to therapy is unique to each individual, necessitating personalised, or ‘precision’ medical
care. This demand extends to thyroid cancer; ~ 10% patients fail to respond to radioiodine treatment due to loss of
phenotypic differentiation, exposing the patient to unnecessary ionising radiation, as well as delaying treatment
with alternative therapies.
Methods: Human thyroid tissue (n = 23, malignant and benign) was live-sliced (5 mm diameter × 350-500 μm
thickness) then analysed or incorporated into a microfluidic culture device for 96 h (37 °C). Successful
maintenance of tissue was verified by histological (H&E), flow cytometric propidium iodide or trypan blue
uptake, immunohistochemical (Ki67 detection/ BrdU incorporation) and functional analysis (thyroxine [T4]
output) in addition to analysis of culture effluent for the cell death markers lactate dehydrogenase (LDH) and
dead-cell protease (DCP). Apoptosis was investigated by Terminal deoxynucleotidyl transferase dUTP nick end
labelling (TUNEL). Differentiation was assessed by evaluation of thyroid transcription factor (TTF1) and sodium
iodide symporter (NIS) expression (western blotting).
Results: Maintenance of gross tissue architecture was observed. Analysis of dissociated primary thyroid cells
using flow cytometry both prior to and post culture demonstrated no significant change in the proportion
of viable cells. LDH and DCP release from on-chip thyroid tissue indicated that after an initial raised level of
release, signifying cellular damage, detectable levels dropped markedly. A significant increase in apoptosis
(p < 0.01) was observed after tissue was perfused with etoposide and JNK inhibitor, but not in control tissue
incubated for the same time period. No significant difference in Ki-67 positivity or TTF1/NIS expression was
detected between fresh and post-culture thyroid tissue samples, moreover BrdU positive nuclei indicated on-
chip cellular proliferation. Cultured thyroid explants were functionally viable as determined by production of
T4 throughout the culture period.
Conclusions: The described microfluidic platform can maintain the viability of thyroid tissue slices ex vivo
for a minimum of four days, providing a platform for the assessment of thyroid tissue radioiodine sensitivity/adjuvant
therapies in real time.
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Background
Thyroid carcinoma (TC) is the most common malignant
disease of the human endocrine system, accounting for
~ 2.1% of all cancer cases worldwide, and disproportion-
ately affecting women [1]. The incidence of TC has in-
creased by 139% since the early 1990’s in the United
Kingdom, with a particular increase in the diagnosis of
papillary TC (PTC; Cancer Research UK [2018]). PTC,
along with follicular-TC (FTC), form the differentiated
TC group (DTC), which represent ~ 90% of all thyroid
malignancies [2]. Patients with DTC have a 10-year sur-
vival rate of 90%, underpinned by an efficacious treat-
ment regimen, which includes thyroidectomy followed
by remnant and metastatic ablation using radioactive
iodine (131I).
Treatment, using 131I, capitalises on the ability of thyr-
ocytes to absorb iodide (I−) for thyroid hormone biosyn-
thesis. I− is transported across the basolateral membrane
of thyrocytes by the sodium iodide symporter (NIS)
using the sodium gradient generated by Na+/K+-ATPase
[3]. Due to the essential involvement of the NIS in thy-
roid hormone biosynthesis and thus human metabolism
in general, expression of the NIS is tightly regulated. In
thyroid cancer, thyroid peroxidase (TPO) activity, and
thus organification of free iodide is reduced. Oxidised
iodine possesses a significantly longer retention time
than free iodide, leading to a considerably reduced ef-
fective half-life in the malignant compared with the be-
nign thyroid (0.5–3 days vs. 3–7 days, respectively; [4]).
Despite this, treatment of DTC using 131I remains an ef-
fective means of eradicating remnant and metastatic ma-
lignant foci when a high dose can be delivered to the
target tissue [5]. However, in approximately 15% of DTC
cases, basolateral expression of the NIS is lost, due to
phenotypic de-differentiation of thyrocytes, rendering
131I therapy ineffective [6]. Within this cohort of pa-
tients, the use of 131I therapy is negated, as thyrocytes
cannot concentrate 131I, leading to a marked reduction
in patient survival (only 10% alive at 10-years, mean sur-
vival 3–5 years; [7]). Treatment of advanced, 131I refrac-
tory TC using traditional systemic therapies including
doxorubicin has limited efficacy with a high toxicity rate
[8]. Alternative therapy using relatively new-to-market
tyrosine-kinase inhibitors (TKI), particularly sorafenib
and lenvatinib, has garnered significant interest and has
shown objective response rates with significantly im-
proved progression-free survival [9, 10]. Currently it is
not possible to predict accurately a lack of response to
131I prior to administration, thus patients have a delay
before receiving effective adjuvant therapy [11]. Al-
though it is well accepted that iodide uptake is typically
reduced in malignant thyroid tissue relative to surround-
ing tissue [12], the molecular underpinnings have not
yet been fully elucidated. A previous study by Min et al.
[6] investigated the relationship between NIS expression
and 131I uptake in recurrent TC using immunohisto-
chemical (IHC) analysis. They found that although
lesional NIS expression predicted 131I uptake with 100%
specificity, the sensitivity of this method was just 50%
(14 of 28 patients with positive 131I uptake had negative
NIS staining. Similarly, Arturi et al. [13] found, in a
smaller study using RT-PCR, that only 4 out of 8 (50%)
primary DTC with distant metastases and negative 131I
uptake lacked NIS gene expression in the primary lesion;
thus indicating that assessment of NIS expression is cer-
tainly not an infallible means of evaluating 131I uptake.
Furthermore, Saito et al. [14] unexpectedly detected in-
creased NIS mRNA and protein levels in PTC tissue
compared with normal thyroid tissue. This variability
suggests that reduced iodide uptake is perhaps due to
failure to target or retain NIS protein at the basolateral
membrane [15], rather than abrogated NIS protein
production.
The microfluidic system described herein uses preci-
sion cut tissue slices (PCTS) which maintain the multi-
cellular 3D architecture of the thyroid tissue essential
for intercellular communication, which is not well reca-
pitulated in standard in vitro systems. Two previous
studies have employed static culture of thyroid tissue ex-
plants: Russo et al. [16] investigated apoptosis subse-
quent to 131I treatment in 1mm3 tissue fragments,
whereas Nagy et al. [17] examined the effect of various
hormones and cytokines on the proliferation of 2mm3
thyroid fragments. The results from these studies dem-
onstrated that thyroid tissue cultured ex vivo can re-
spond to external stimuli, however clinical utility was
not assessed.
The bespoke device described in this manuscript
mimics the in vivo vasculature and lymphatics by allow-
ing continual perfusion of explanted tissue, along with
removal of waste products and allows precise control of
drug delivery [18]. Future treatment of ex vivo thyroid
tissue maintained in this device with 131I, holds potential
for a more realistic estimation of 131I treatment success
by assaying not only uptake, but resultant cell death.
The aim of this study was to characterise a reproducible,
easy to use, microfluidic system to maintain precision
sliced ex vivo thyroid tissue for up to 96 h.
Methods
Fabrication of a microfluidic culture device
Two polyether ether ketone plastic plates (PEEK; Direct
Plastics, Sheffield, UK), both 30mm× 14mm in size
(Fig. 1-a), were milled centrally to produce threaded axial
holes to which inlet and outlet ethylene tetrafluoroethylene
tubing (ETFE; 0.8mm internal diameter; Kinesis, IDEX
Health & Science, Cambridge, UK) was attached via coned
adapters (LabSmith, Mengel Engineering, Denmark). In
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addition, four ¼ inch (6.35mm) holes were made in both
PEEK plates to allow the insertion of nylon screws in order
to secure the unit after sample addition. A central cylin-
drical recess (10 × 4mm) was drilled in each PEEK plate to
house a porous sintered pyrex disc (Fig. 1-a; The Lab
Warehouse, Grays, UK). Finally, a silicone gasket (30mm
diameter, 1mm sheet silicone) with a 6mm central hole to
create a tissue well, was placed between the two PEEK
plates.
Sample collection and preparation
Human thyroid tissue samples (n = 23 malignant; n = 14
benign) were collected at the point of surgical resection
during thyroidectomy following written informed con-
sent under ethical approval from North East-Newcastle
and North Tyneside Research Ethics Committee (15/NE/
0412) and Hull and East Yorkshire NHS Trust R&D
(R1925). Benign thyroid tissue was collected alongside
malignant tissue when deemed practicable by consultant
surgeon JE (n = 14). Details of obtained tissue specimens
are summarised in Table 1. Tissue samples were trans-
ported to the laboratory in ice-cold complete medium,
then processed, allowing culture initiation within 60 min
of surgical excision. Tissue was immobilised on a piece
of cork and sliced at a thickness of either 350 or 500 μm
in ice-cold PBS using a vibratome (Leica VT1200S, Mil-
ton Keynes, UK) with a blade speed of 0.1 mm s− 1 and
amplitude of 2.5 mm. A skin biopsy punch (Stiefel,
Middlesex, UK) was used to generate PCTS 5mm in
diameter. Each PCTS was weighed before insertion into
the device. Where samples sizes differ across experi-
mental time-points this was due to difficulties in ef-
fluent collection, sample numbers collected are
provided in figures.
PCTS culture set up
Dulbecco’s modified eagles medium (DMEM; GE Health-
care, Yeovil, Somerset, UK) containing 10% (v/v) heat inac-
tivated foetal bovine serum (FBS; Biosera, East Sussex, UK),
penicillin/streptomycin (0.1 U/ml and 0.1mg/ml respect-
ively, GE healthcare), 0.4mM glutamine (GE healthcare)
and 2.5 μg/ml Amphotericin B (Life Technologies, Paisley,
UK) was supplemented with thyrotropin [TSH; 2 mIU/L
(normal serum 0.3–5 mIU/L)] and sodium iodide (0.1 μg/
ml). ‘Complete medium’ was then loaded into a 20ml syr-
inge and connected to the 2-part adapter and ETFE tubing
via a 0.22 μm filter (Fig. 1; Millipore, Watford, UK). The
PCTS was loaded onto a 70 μm nylon porous membrane
placed on top of the sintered disc in the inlet PEEK plate,
and the outlet PEEK plate was then secured in place using
nylon screws. The syringe was connected to a Harvard PhD
2000 syringe pump (Harvard, Cambridge, UK), which pro-
vided a pressure driven perfusion rate of 2 μl min− 1. The
culture device was maintained at 37 °C inside an incubator
for 96H. media coming off the chip was collected in 1.5ml
polypropylene tubes after 2 h culture, then in 15ml poly-
propylene tubes once per day thereafter. Where required,
for proliferation analyses, the thymidine analogue Bromo-
deoxyuridine (BrdU; Sigma-Aldrich, Gillingham, UK) was
Fig. 1 PCTS Culture device. a: Photograph illustrating device assembly. Two polyether ether ketone (PEEK) plastic plates, each with a medial recess to
house a sintered pyrex disk, affix to sandwich a silicone gasket with a central cavity in which the precision cut tissue slice (PCTS) is contained. A 70 μM
porous nylon membrane separates the tissue from the sintered disk (not shown). b: Photograph of an assembled PCTS culture device with external
dimensions. c: Schematic of PCTS culture device. Component parts numerically labelled: 1, PEEK plastic plates; 2, glass sintered pyrex disk; 3, central
silicone gasket; 4, tumour tissue sample
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added, at 10 μM final concentration, to the complete
medium for the final 24 h of culture [19].
Tissue embedding and morphological analysis
Fresh and post-culture tissue samples were either frozen
in Tissue-Tek OCT (optimum cutting temperature;
Sakura, Berkshire, UK) medium, using liquid nitrogen-
cooled 2-methylbutane (Sigma-Aldrich), or fixed in 4%
paraformaldehyde (PFA) for 24 h. PFA fixed tissues were
then dehydrated through an ethanol gradient (70, 90, 95,
100%), incubated with two changes of molten paraffin
wax, then embedded and allowed to cool. Frozen tissue
sections were cut at a thickness of 8 μm using a Leica
CM1100 cryostat and fixed for 20min in − 20 °C cooled
methanol before standard staining using Haematoxylin
and Eosin (H&E; [20]). PFA fixed, paraffin embedded
(PFPE) tissues were sectioned using a Leica RM2135
microtome (5 μm).
Measurement of lactate dehydrogenase release
Lactate dehydrogenase (LDH) is a cytosolic enzyme re-
leased from the cell after plasma membrane damage
[21]. As membrane damage is synonymous with cell
death, its release allows monitoring of the loss of cell
viability (Cytotoxicity Detection Kit Plus, Roche, UK).
Culture effluent (n = 14 malignant, n = 10 benign patient
samples) was collected daily and stored at 4 °C until the
end of the culture period (96 h). In some cases (n = 7)
tissue was removed from the culture system at the end
of the 96 h incubation and exposed to a 10% (v/v) lysis
buffer overnight to induce cell death and subsequent
LDH release. The assay was conducted following the
manufacturer’s protocol and results expressed as an
average of duplicate readings normalised per mg of thy-
roid tissue.
Measurement of protease release
The CytoTox-Glo™ Cytotoxicity Assay (Promega, South-
ampton, UK) allows measurement of cell death using a
luminogenic peptide substrate (alanyl-alanylphenylalany-
l-aminoluciferin; AAF-Glo™ Substrate) to measure the ac-
tivity of proteases released from non-viable cells that have
lost membrane integrity. Culture effluent samples (includ-
ing positive controls exposed to 10% (v/v) lysis buffer;
100 μl per well) were added in duplicate to a 96-well
white-walled microplate. Malignant tissue samples were
prioritised for use in DCP analysis. Assay Reagent (50 μl)
was then added to all wells and mixed briefly by orbital
shaking. The reaction was incubated at room temperature
for 15min, before luminescence was measured using a
Victor multilabel plate reader according to the supplier’s
protocol (n = 7; PerkinElmer, Coventry, UK).
Viability analysis of dissociated cells
Malignant thyroid tissue was dissociated into a single
cell suspension (n = 3) prior to and after maintenance on
the device by initial mincing using scalpels followed by a
2 h incubation (37 °C; 5% CO2) with 0.024% (w/v) Colla-
genase IV (Sigma-Aldrich: Dorset, UK) and 0.02% (w/v)
DNase I (Roche, Herefordshire, UK) in complete
medium under constant rotation. The resultant suspen-
sion was passed through a 70 μm filter (BD Biosciences,
Oxford, UK) prior to centrifugation at 400 x g for 5 min,
to pellet the cells. The cell pellet was resuspended in 1
ml of complete medium before viability was quantified
using trypan blue exclusion. The cells were rinsed in
PBS (Oxoid, Thermo Scientific, Hampshire, UK)/ BSA
(2.5 g/L; Thermo Scientific, Loughborough, UK)/Azide
(0.0624% [v/v]; Sigma-Aldrich) and dead cells were
stained by the addition of propidium iodide (500 μg ml−
Table 1 Disease and patient characteristics of thyroid specimens
used in this study
No Tumour stage Patient age range (years) Tissue received
1 T2NXMX 40–50 M
2 T4aN1bMX 40–50 M
3 T3aNXMX 40–50 M
4 BG 50–60 B
5 T2NXMX 50–60 M,B
6 T3N1bMX 20–30 M
7 T4N0M0 80–90 M
8 T1aNXMX 60–70 M
9 BG 60–70 B
10 T2N1BMX 30–40 M,B
11 T3N1aMX 50–60 M
12 BG 30–40 B
13 BG 50–60 B
14 T4N0M1 50–60 M
15 T1aN1bMX 40–50 M
16 T1bNXMX 40–50 M,B
17 T3aNXMX 10–20 M
18 T3bN1aMX 40–50 M,B
19 T1NXMX 60–70 M,B
20 T1aNXMX 10–20 M
21 T3AN1bMX 30–40 M,B
22 T3aN1bM0 20–30 M
23 T1aNXMX 40–50 M,B
24 T3N1bM0 30–40 M,B
25 T2NXMX 70–80 M,B
26 T3aNXMX 60–70 M
27 T4aN1bMX 70–80 M,B
BG Benign goitre, M Malignant tissue, B Benign tissue
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1). Cells were acquired immediately using a FACS Cali-
bur flow cytometer (BD Biosciences) alongside unstained
cells as a reference and results were analysed using Cell
Quest Pro software, version 6.0.
Terminal deoxynucleotidyl transferase-mediated dUTP
nick-end labelling (TUNEL) assay
Frozen tissue sections were defrosted for 5 min prior to
fixing in 4% PFA for 20 min at room temperature. PFPE
tissue sections were dewaxed in xylene (20 min) then
rehydrated in 100, 90 and 70% ethanol (2 min per wash).
Sections were treated for 20 min at 37 °C (PFPE tissue)
or 2 min on ice (frozen tissue) with 0.1% proteinase K/
1% TrisHCl in dH20. Sections were washed twice with
PBS for 5 min and apoptotic cells were labelled using an
In Situ Cell Death Detection Kit (Roche, UK) according
to the manufacturer’s guidelines. Negative control sec-
tions were incubated with 50 μl label solution only,
whereas test sections were incubated with both the label
and enzyme solution. Sections were counterstained using
a DAPI-hardset mounting medium (Vector Laboratories,
UK) before fluorescence was evaluated using an ImageX-
press Micro 4 Imaging System (Molecular Devices, Cali-
fornia, USA). Produced tiled images were stitched to
create a single composite image before apoptotic nuclei
were quantified using ImageJ (Fiji plugin [22]).
Treatment of thyroid tissue with etoposide and SP600125
Thyroid explants were exposed to etoposide and
SP600125 for the complete (96 h) culture period in order
to examine the ability of the system to induce a response
which was then quantifiable using TUNEL staining. Eto-
poside, a topoisomerase II inhibitor, and SP600125, a
JNK inhibitor, were added to complete culture medium
at a concentration of 20 μM, then perfused through the
culture system under the same conditions as control
samples.
Immunohistochemical analyses
Frozen tissue sections (8 μm) were fixed in pre-cooled
(− 20 °C) acetone for 20 min. Frozen tissue sections to be
stained with anti-BrdU primary antibody were trans-
ferred into 2M HCl for 30 min to denature the DNA
and allow access of the antibody to the incorporated
BrdU before being neutralised in borate buffer (0.2 M
boric acid, 0.05M sodium tetraborate [pH 8.4]; 2 × 5 min
washes). PFPE tissue sections were dewaxed and rehy-
drated as previously described. Endogenous peroxidases
were blocked in 3% (v/v) H2O2 (Fisher Scientific, Lough-
borough, UK) in acetone for 15 min. Antigen retrieval
was carried out on paraffin embedded tissue sections by
microwave boiling within Antigen Unmasking Solution
(citrate based; pH 6.0, Vector Laboratories, Peterbor-
ough, UK) for 20 min. Slides were loaded into Sequenza™
racks and sections were incubated with normal horse
blocking serum (Vectastain Elite ABC kit, Vector La-
boratories) for 20 min. The addition of avidin D solution
and, after a TBS wash, biotin solution (Vector Labora-
tories) for 15 min blocked non-specific binding of the
avidin/biotin system.
Sections were incubated with primary antibody or
matched isotype control antibody overnight at 4 °C [Ki67
clone MIB1, 1:100 (Dako, Agilent, Stockport, UK)]; [BrdU
clone 3D4, 1:50 (BD Biosciences)]; [TTF1 clone EP1584Y,
1:250 (AbCam)]. Following a TBS wash sections were in-
cubated with secondary antibody (Vectastain Elite ABC
kit) for 30min followed by ABC detection reagent for 30
min. Colour was developed using 3,3′-diaminobenzidine
(DAB; Sigma-Aldrich) and sections counterstained with
Harris Haematoxylin. Sections were dehydrated and
cleared through graded alcohols and histoclear™ (Scientific
laboratory supplies, Nottingham, UK) then mounted using
histomount (Scientific laboratory supplies). The percent-
age of DAB positive cells was assessed across five separate
fields using the online applet Immunoratio (http://153.1.
200.58:8080/immunoratio/; [23]).
Assessment of NIS protein expression by Western
blotting
Both fresh and post-culture thyroid tissue samples were
minced using scalpel blades in ice cold RIPA buffer (Sig-
ma-Aldrich) containing 1% (v/v) protease inhibitors
(Roche) and sonicated for 1 min before being agitated
using a MACSmix™ tube rotator (2 h, 4 °C; Miltenyi Bio-
tec, Surrey, UK). Samples were then centrifuged at
16,000 x g for 20 min at 4 °C, before the supernatant was
aliquoted and frozen (− 80 °C). Proteins were quantified
using a Pierce™ BCA Protein Assay Kit (Thermo Scien-
tific) then 10 μg was resolved on a 4% (v/v) stacking,
12% (v/v) separating sodium dodecyl sulfate–polyacryl-
amide gel in a Mini-PROTEAN® system, before being
transferred onto nitrocellulose membranes using a
Trans-Blot Turbo™ (both Bio-Rad, Watford, UK) and
blocked in 4% bovine serum albumin (BSA) in
TBS-Tween overnight. NIS was detected using a rabbit
anti-human polyclonal antibody (ab199410, Abcam,
Cambridge, UK) diluted 1:500. The house keeping gene
β-actin was detected using a mouse anti-human anti-
body (sc-516,102, Santa-Cruz Biotechnology, Heidelberg,
Germany) diluted 1:10,000. Blots were developed using
SuperSignal™ West Pico PLUS Chemiluminescent Sub-
strate (Thermo Scientific) and Radiomat LS film (Agfa
Healthcare, Middlesex, UK). Densitometry of bands was
analysed using a Gel Doc system (Bio-Rad).
Measurement of thyroxine release by ELISA
Thyroxine (T4) is the principal hormone released by the
thyroid gland, thus, its release from on-chip thyroid
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tissue was investigated using an enzyme-linked immuno-
sorbent assay (ELISA, Abcam), according to the manu-
facturer’s instructions, as a measure of ex vivo
functionality. Briefly, effluent samples (n = 7 malignant,
n = 7 benign), controls and standards (25 μl) were loaded
in duplicate into a pre-coated 96 well plate, followed by
100 μl working concentration of conjugate reagent. The
plate was incubated for 60 min at room temperature.
Each well was washed 5 times with distilled water before
TMB (3,3′,5,5′-Tetramethylbenzidine; 100 μl) reagent
was added before a further 20-min incubation. The reac-
tion was stopped by the addition of 100 μl stop solution
(2 N Sulphuric acid [H2SO4] VWR, Leicestershire, UK)
to each well. Absorbance was measured at 450 nm using
a Multiskan plate reader (Thermo Scientific). T4 con-
centration in each sample was determined from the
standard curve and normalised per mg of thyroid tissue.
Results
The morphology of both freshly resected and post-cul-
ture (96 h) ex vivo thyroid tissue sections was assessed
by H&E staining and showed preservation of gross
morphology, with retention of tissue cohesion (Fig. 2).
The follicular structure, typical of in vivo thyroid tissue,
was clearly displayed in both fresh and post-culture tissue
samples. Inter-tumour variation in cellularity and follicle
size is clear, however these differences are retained in
tumour tissue throughout culture.
Culture effluent was sampled throughout the 96 h cul-
ture period and examined for the presence of two markers
of cell death, LDH and DCP. An initial raised level of
LDH release was observed within the first 2 h of culture
setup (Fig. 3a), which reduced after 24 h and remained
consistently low for the remaining 72 h, until tissue was
exposed to 10% (v/v) lysis buffer, which led to an average
increase in LDH release from 0.01 ± 0.002 to 0.304 ± 0.06
and 0.005 ± 0.001 to 0.35 ± 0.03 absorbance units mg− 1 in
malignant and benign thyroid tissue, respectively. No dif-
ference in LDH release was found between the malignant
and the benign tissue. DCP release by cells in the culture
system followed a profile similar to that of LDH release
(Fig. 3b), with the level being relatively high in the first 2 h
of culture before decreasing after 24 h. DCP release
reached a minimum after 72 h, with only 41.53 ± 28.33
RLU mg− 1 detectable. Concordant with LDH release, pur-
poseful lysis of cultured thyroid tissue subsequent to 96 h
culture induced a > 1000-fold increase in detectable DCP.
No significant difference in viability between fresh
(27.3 ± 7.3%) and post-96 h cultured (24.6 ± 8.8%) malig-
nant thyroid tissue samples was observed using PI stain-
ing to (Fig. 4; n = 3; p = 0.19). These data were consistent
with results using trypan blue exclusion to represent cell
viability, whereby the mean proportion of viable dissoci-
ated cells was 38.33 ± 7.3% in fresh thyroid tissue prior
to culture and 34 ± 9.5% in tissue after a 96 h culture
period (Fig. 4; n = 3; p = 0.37). The proportion of apop-
totic cells in both fresh and post-culture (+ 96 h) malig-
nant thyroid tissues was assessed by TUNEL staining (n
= 9) and a small, non-significant, increase in apoptotic
cells was observed in the post-culture tissue (5.59 ±
0.99%) compared with the fresh tissue (2.77 ± 0.89%;
Fig. 4-c and d). Moreover, on-chip treatment of thyroid
explants with etoposide (topoisomerase II inhibitor) and
SP600125 (JNK inhibitor) caused a significant increase
Fig. 2 Haematoxylin and eosin stained 8 μM frozen thyroid sections. Representative images from two patients a and b. Top: fresh tissue frozen
prior to culture. Bottom: tissue frozen subsequent to 96 h culture within the PCTS device. Images are shown at both 100x and 400x magnification
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in cellular apoptosis after 96 h treatment, compared
to untreated thyroid tissue (15.25 and 14.24% vs.
5.59%; p = 0.0025 and p = 0.0069 respectively; Fig. 4).
Cell proliferation within the thyroid tumour tissue was
investigated by IHC. Two markers were used; Ki67, a nu-
clear protein expressed during all active phases of the cell
cycle (non-senescent cells) and BrdU which is incorpo-
rated during s-phase of the cell cycle [24]. This analysis
demonstrated that proliferating cells were detectable in
both freshly resected tissue and post-culture tissue. The
mean percentage of Ki-67 positive nuclei was 1.45 ± 0.33%
and 1.32 ± 0.34% in fresh and post-culture tissue (n = 8),
respectively; no significant difference in the quantity of
proliferating cells between fresh and post-culture malig-
nant thyroid tissue was observed (p = 0.32). BrdU, which
was perfused through the culture system for the final 24 h
culture on the device, was clearly visible as incorporated
into the cell nuclei of proliferating cells post-culture, illus-
trating that on-chip cell proliferation was occurring
(Fig. 5). Subsequent to a 24 h perfusion with 10 μM BrdU,
12.09 ± 4.38% cells stained positive for BrdU incorporation
(n = 3). Thyroid transcription factor 1 (TTF1) is crucial for
thyroidal organogenesis and differentiation which, along
with two other factors, paired box gene 8 (PAX8) and
TTF2 (FOXE1), governs the expression of thyroglobulin
(TG), thyroperoxidase (TPO) and NIS [25]. The expres-
sion of TTF1 was characterised in fresh (0 h) and
post-culture (+ 96 h) malignant thyroid tissue; the staining
pattern of TTF1 was maintained throughout culture in
the microfluidic device (Fig. 5).
Fig. 3 Measurement of lactate dehydrogenase (LDH) and dead-cell protease (DCP) release into culture effluent for the evaluation of cell membrane
damage. a: Lactate dehydrogenase release from both malignant and benign thyroid tissue (n = 14 and n = 10, respectively unless otherwise stated;
relative absorbance of formazan reaction product) during on-chip culture of thyroid tissue normalised per mg starting tissue wet weight. b: Level of
relative light units (RLU) produced as a result of cleavage of the luminogenic assay substrate by dead cell protease released per mg of on-chip thyroid
tissue over the 96 h culture period (n = 11). Lysis buffer (10% v/v) was added to homogenised tissue after 96 h culture (arrow) in order to purposefully
rupture cell membranes and induce complete release of remaining LDH/ DCP
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As expression of the NIS is crucial for adequate re-
sponse to treatment to I131, it was important to ensure
that 96 h culture of malignant thyroid explants within
our MF device did not affect NIS protein levels. NIS ex-
pression was investigated in both freshly resected and
post-culture malignant thyroid tissue and showed that
there was no statistically significant difference between
the density of NIS protein bands in fresh and cultured
thyroid tissue, normalised to β-actin (Fig. 6; n = 5), indi-
cating that the expression of NIS was maintained
throughout culture.
The functionality of cultured ex vivo thyroid tissue was
investigated by its capability to synthesise and release the
primary thyroid hormone, T4. Production of T4 occurs as
a result of a cycle of biochemical reactions occurring ex-
clusively within the thyroid. Culture effluent was analysed
by ELISA for the presence of T4 (n = 7 malignant tissue;
n = 7 benign tissue). Data indicate that T4 release by both
malignant and benign thyroid explants follows a similar
overall trend, with an initially raised level of T4 produc-
tion over the first 24 h, stabilising after 48 h (Fig. 7). Inter-
estingly, T4 release by benign thyroid explants was
consistently higher at each timepoint in comparison to
malignant tissue and average T4 output throughout the
complete culture period was significantly higher in benign
tissue (0.29 ± 0.09 μg/dl mg− 1) than in malignant tissue
(0.14 ± 0.03 μg/dl mg− 1; Fig. 7; p = < 0.05).
Discussion
The current study aimed to characterise the ability of a
PCTS device to maintain viable thyroid tissue explants
over a 96 h period with a view towards therapeutic inter-
rogation. Human tissue explants from human head and
neck tumours, intestine and mouse brain have been
maintained using similar microfluidic culture systems
[20, 26, 27] however this is, to the best of the authors’
knowledge, the first time ex vivo human thyroid tissue
has been cultured in a robust, easy-to-use, platform. Tis-
sue sections taken from both fresh and PCTS-cultured
thyroid tissue analysed by haematoxylin and eosin and
IHC staining demonstrated that morphology was pre-
served in tissue which had been cultured in the device
for 96 h, validated by a consultant histopathologist. Re-
sults observed agree with those shown in similar studies
from the group, whereby head and neck squamous cell
Fig. 4 Cellular viability and apoptosis in freshly resected, control and treated thyroid tumour tissue. Cellular ability to prevent both PI (a) and TB
(b) transit across the plasma membrane was employed as a proxy of viability (n = 3, mean + SEM). No significant difference was observed between
fresh and untreated control thyroid tissue. c: Terminal deoxynucleotidyl transferase dUTP nick end labelling in both fresh (+ 0 h) and post-culture (+ 96
h) malignant thyroid tissue explants demonstrated no difference in the proportion of apoptotic cells in post-culture specimens (n = 9; 2.78 vs. 5.59%,
p = 0.51 [paired t-test]). Treatment of cultured thyroid explants with etoposide and SP600125 resulted in a significant increase in apoptosis (15.25 and
14.24%, respectively) which were both significantly increased compared to untreated explants (n = 5; p = < 0.001). d: Representative images of both
pre-MF and untreated post-MF thyroid explants illustrating apoptotic cells (FITC; green) counterstained with DAPI (blue)
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carcinoma and full thickness intestinal tissue also dem-
onstrated a preservation of tissue morphology after 72 h
on-chip culture [18, 20]. The gross inter-patient morph-
ology of tissue specimens was variable, and heterogen-
eity was visible within each tissue sample. Areas of
typical thyroidal histology exhibiting follicular architec-
ture often neighboured regions of densely arranged cells
or fibrous stroma. This inter- and intra- patient hetero-
geneity was expected and was also presented in a study
by Radu et al. [28], who speculated that the morpho-
logical variation in thyroid carcinoma is due to manifest-
ation of diverse tumour cell clones under the influence
of the same etio-pathogenic factors. It will therefore be
necessary to run multiple PCTS chips from the same pa-
tient when interrogating the tissue with different treat-
ment regimens.
The release of both LDH and DCP as markers of cell
membrane integrity was assayed throughout the culture
period; loss of cellular plasma membrane integrity is
synonymous with loss of cellular viability [29] and
microfluidic culture offers a unique means of evaluating
this in real time. As anticipated, the release of these two
markers followed similar patterns, with a higher level at
the beginning of the culture period, attributed to the
damage caused to the tissue during preparation, which
decreased during the remainder of the experiment. The
relatively low LDH/ DCP release once the tissue had re-
covered from the initial cellular damage during set-up,
which has also been experienced in previous studies [30,
31], indicates cultured explants do not undergo further
degradation due to factors such as sheer stress or lack of
oxygen within the culture chamber. Deliberate lysis of
cultured tissue resulted in an increase in both LDH and
DCP, suggesting that a significant number of viable cells
remain after 96 h in the PCTS device, which agrees with
the morphological assessment. A similar pattern has
been observed studies from other groups where stabilisa-
tion of LDH release was seen after four days in a
four-organ-chip model [32] and after six days in a liver/
skin co-culture [33]. The discrepancy in time taken for
tissue to recover from the initial damage could poten-
tially be attributable to either the difference in tissue
type, the system used or the presence of malignancy in
the current system.
Fig. 5 Percentage Ki-67 positivity in fresh (+ 0 h) and post-culture (+ 96 h) thyroid tumour tissue. Mean Ki-67 positivity was 1.52 ± 0.52%
and 1.3 ± 0.34% in fresh and post-culture tissue, respectively; no significant difference was observed (n = 8; p = 0.32 [paired t-test]). Inset:
Representative photomicrographs of Ki67, BrdU and TTF1 positive brown nuclei and counterstained with haematoxylin (× 400). BrdU
staining is only shown in cultured tissue due to the requirement of perfusion with the molecule in order to elicit its incorporation and
subsequent detection; 12.09 ± 4.38% cells stained positive for BrdU incorporation (n = 3)
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Tissue dissociation using a combined mechanical and
enzymatic method offered an alternative means of investi-
gating the survival of individual cells constituting the gross
thyroid explants, by monitoring the ability of propidium
iodide and trypan blue to traverse the cellular membrane.
Again, no statistically significant difference in mean cellu-
lar viability was observed between samples which had
been dispersed prior to, or after PCTS-culture, further
demonstrating that on-chip maintenance was not causing
increased cell death. This was despite the fact that the
overall viability of cells after dispersal from gross tumour
material was unexpectedly low (< 40%), presumably due to
injury caused by the enzymatic (collagenase IV, DNase II)
and mechanical (mincing of gross tissue using scalpel
blades) process of dissociation. The high level of cell death
observed in the current study is in contrast to Li et al. [34]
who provided a mean cell viability of 65.66% (±4.96) using
trypan blue staining following disaggregation of murine
pancreatic fragments using collagenase IV. As malignant
tumour tissue is marked by regions of necrosis owing to
rapid oncogene-driven proliferation not supported by an
adequate vascular bed [35], it is a possibility that presence
of necrotic cells contributed to the lower overall viability
in the current study. The viability of cells dispersed from
human head and neck cancer specimens was assessed by
flow cytometry in a separate study and produced viabilities
ranging from 24 to 92% [36], partially aligning with the re-
sults seen here.
Fig. 7 Thyroxine (T4) release by on-chip thyroid tissue. Concentration of T4 in effluent samples collected throughout the culture of both malignant
(n = 7) and benign (n = 7) thyroid tissue explants on the PCTS device. Overall T4 release by benign thyroid tissue was significantly higher than that of
malignant thyroid tissue (p = 0.03; 2-way ANOVA). Results normalised mg− 1 tissue
Fig. 6 Assessment of sodium iodide symporter (NIS) protein expression by Western blotting. Band densitometry confirmed that NIS expression
was not significantly altered by the microfluidic culture of thyroid tumour tissue explants (n = 5). [+] and [−] represent protein extracted from
tumour tissue with and without on-chip culture respectively. 1–5 indicates five separate patient samples and K1 is protein extracted from the
thyroid cell line
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To further characterise on-chip tissue kinetics, the
proportion of thyroid cells undergoing apoptosis was
elucidated through the labelling of 3-OH termini of
DNA strand breaks in situ, produced due to endonucle-
ase mediated DNA fragmentation, characteristic of DNA
degradation and late-stage apoptosis [37]. The culture of
thyroid explants within the microfluidic device showed
no change in the proportion of apoptotic cells. Similar
studies have, however, reported comparable levels of
apoptosis in untreated specimens’ post-microfluidic cul-
ture. Cheah et al. [22], found an apoptotic fraction of <
10% within untreated head and neck squamous cell car-
cinoma (HNSCC), whilst Wang et al. [38] also saw <
10% apoptosis post-culture in brain organoids, compared
to ~ 40% apoptosis in organoids subjected to static cul-
ture conditions. The increase in apoptosis observed in
this study was not mirrored in other tests of viability
such as PI/TB uptake and LDH/DCP leakage data as the
latter assays rely on loss of membrane integrity, syn-
onymous with necrotic cell death [38], to facilitate detec-
tion of leaked cellular components (LDH/DCP) or PI/
TB labelled cells. It is feasible that, if cultured for an ex-
tended period of time, a decrease in cell viability would
also be observed using PI/TB uptake and LDH/DCP
leakage assays, due to the occurrence of cell death by al-
ternative mechanisms such as secondary necrosis, char-
acterised by progressive loss of plasma membrane
integrity, through caspase-3-dependent cleavage of the
GSDMD-like protein DFNA5 [38, 39]. Furthermore,
on-chip treatment of thyroid explants with 20 μM etopo-
side and SP600125 demonstrates the devices’ utility as a
drug screening system. Perfusion of thyroid explants
with either agent for 96 h resulted in significantly in-
creased levels of apoptosis as examined by TUNEL
staining. Etoposide is a well-characterised inducer of
apoptosis [40] whilst SP600125 is a multikinase inhibitor
which has been shown to have both anti-proliferative
and migratory effects in thyroid cell lines [41].
IHC analysis was used to investigate the ability of
the cells within the cultured tissue to proliferate. The
Ki67 antigen is present in all active stages of the cell
cycle, except for G0, in which cells are in a quiescent
state [42]. Previous studies have attempted to use
Ki67 labelling index to aid diagnosis in thyroid neo-
plasms, however it has shown little value in this set-
ting due to the low labelling index in most thyroid
lesions (< 1% in 57% PTC samples tested; [43]). In
agreement, Ki67-positive brown stained cells were de-
tectable at low levels (< 2%) in tissue sections in the
current study after 96 h within the PCTS device indi-
cating the presence of a small number of proliferating
cells. Furthermore, comparison of the proliferating
cell population in both fresh and post-culture thyroid
tissue revealed no significant difference.
BrdU staining was also employed, having the added ad-
vantage of demonstrating definitive on-chip division as
BrdU is incorporated into de novo DNA during the
S-phase of the cell cycle as a substitute for thymidine and
is detectable by IHC [44]. Cells with BrdU positive nuclei
(12.09%) were evident in thyroid tissue samples which had
been maintained for 96 h in the PCTS-culture device, the
final 24 h of which included perfusion with 10 μM BrdU.
Identification of BrdU-positive cells throughout the tissue
both demonstrates the ability of BrdU to perfuse success-
fully through the tissue and moreover the presence of pro-
liferating cells in the S-phase of the cell cycle. A
comparable study by Sart et al. [45] investigated BrdU up-
take in H4-II-EC3 rat hepatoma cells cultivated in both a
2D and 3D spheroid setting. The authors saw a near
2-fold decrease in BrdU positivity in 3D (~ 16%) versus
2D (~ 30%), similar to results observed in this study.
In addition to the viability of the tissue, it was import-
ant to characterise the differentiation of thyroid ex-
plants, in order to examine whether culture within the
microfluidic device could affect the expression of certain
genes crucial for successful treatment with radioiodine.
A previous study conducted by Cirello et al. [46] which
aimed to investigate the effects of the multikinase inhibi-
tor SP600125 on multicellular spheroids derived from
primary thyroid tissue, examined expression of the tran-
scription factor TTF1 as a marker of differentiation. The
authors observed maintenance of TTF1 expression in
spheroids derived from primary thyroid tissue. Encour-
agingly, the pattern of TTF1 staining in post on-chip
culture (+ 96 h) thyroid tissue was equivalent to that of
fresh thyroid tissue, suggesting that culture for 96 h in
the PCTS device did not markedly affect differentiation.
The NIS is an integral plasma membrane glycoprotein
that facilitates the accumulation of I− within the thyroid
gland at a concentration up to 40 times higher than
plasma [47]. Application of I131 for the targeted destruc-
tion of malignant thyroidal tissue has become one of the
most effective radiation regimens available, causing
fewer side effects than other cancer therapies [48]. Loss
of NIS protein expression at the basolateral membrane
of thyrocytes is a well-accepted precursor for reduced ef-
fectiveness of I131 therapy, as demonstrated in poorly
differentiated and undifferentiated thyroid cancers [49,
50]. Therefore, it was necessary to assess the expression
of NIS in thyroid explants which had been subjected to
96 h within the microfluidic device and elucidate
whether its expression was altered. Western blot data re-
vealed that there was no significant change in terms of
NIS protein levels caused by culture within the PCTS
device, indicating that the system is valid for the future
testing of I131 sensitivity.
T4 is exclusively synthesised by thyrocytes as a
pro-hormone, which becomes de-iodinated within target
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tissues to produce the more biologically potent T3
[51]. This natural phenomenon allowed the measure
of T4 release from on-chip PCTS to be investigated
as a measure of tissue functionality. Loss of, or re-
duced functional differentiation, occurs in all thyroid
carcinomas leading to diminished expression of pro-
teins central to thyroid hormone production [52]. In
the current study, benign tissue produced a signifi-
cantly higher volume of T4 than malignant tissue
throughout the culture period, agreeing with the no-
tion that malignant thyroid tissue has a decreased
ability to produce hormone [11]. Detection of T4
within culture supernatant strongly suggests that thy-
roid hormone was synthesised de novo by on-chip
thyroid tissue and that essential components such as
I− are reaching the thyrocytes. In the clinical setting,
the thyroid hormone precursor TG is used as a spe-
cific marker of remnant tumour tissue after thyroid
removal [53]. As our intention was to demonstrate
thyroid tissue functionality, we decided to measure T4
levels as T4 synthesis relies on the success of add-
itional mechanistic steps such as cellular I− uptake
and TG iodination.
Conclusion
Results reported in this work validate the use of a
PCTS device for the maintenance of ex vivo thyroid
tissue which can be used for customising drug treat-
ment. It is proposed to use the system described to
delineate sensitivity of patients suffering from thyroid
carcinoma to treatment with 131I, enabling patient
stratification and reducing incidence of inappropriate
treatment, reducing patient morbidity, whilst saving
NHS resources. This is the first study of its kind to
demonstrate reliably the maintenance of viable ex
vivo thyroid tissue for up to 96 h, with pre- and
post-culture tissue showing high uniformity in terms
of morphology, viability and functionality.
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